PINL:GRPOF - Post by User
Comment by
equity4481on May 15, 2021 9:34am
329 Views
Post# 33209635
RE:May 28
RE:May 28The trial did actually commence on May 6 which I did confirm with TBP a couple days ago.
REBORN1© is being conducted in the United States in collaboration with the Hassman Research Institute, a clinical research organization, who will enroll twenty adults living with breakthrough cancer pain (BTcP) and currently taking stable opioid treatment for breakthrough pain. This innovative Phase 2 pilot, proof-of-concept open-label crossover comparison study will assess whether inhaled QIXLEEF™ will control BTcP faster than immediate-release morphine sulfate tablets.
Apparently a head to head trial takes only 10 days and with the reduction in Covid cases clogging the hospitals, enrolment is not an issue. Based on this information we could very well have information regarding indications by the end of next week.
I too cannot see this possibly failing, considering TBP have already done this form of testing as THC is legal in canada, the development and required strength is documented and millions has been put into development and testing.
This would appear to be a gimmee!!